You searched for "LASIK"
ROP anti-VEGF treatment review
The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP,...Carleton Optical Equipment Ltd is recruiting for its expanding Glaucoma team
Business Manager - We are looking for an ambitious and capable business manager responsible for the South of England.Andy Biart joins Carleton Optical as Surgical Business Manager, South
Carleton are pleased to welcome Andy Biart to their surgical team.Doctor prints cornea on demand!
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Doctor prints cornea on demand! Dr Hideo Kodama from the Nagoya Municipal Industrial Research Institute first...Managing cataract surgery in a patient with diabetic maculopathy
A 56-year-old type 2 diabetic with previously treated bilateral diabetic maculopathy develops a cataract requiring surgery in the right eye. He has had grid laser previously, followed intermittently by intravitreal triamcinalone, Avastin and more recently Lucentis in both eyes. His...
Scleral perforation after strabismus surgery
The aim of this study was to report the incidence, risk factors, treatment and outcomes of scleral perforation as a vision-threatening complication of strabismus surgery. The review included 12 papers: four prospective, two retrospective, two surveys, one review, two animal...
Diclofenac versus Bromfenac after cataract surgery
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used after cataract surgery to reduce inflammation and cystoid macular oedema (CMO). Diclofenac 0.1% is used three to five times daily for 28 days and Bromfenac 0.09% twice daily for 14 days postoperatively. The...
International variations in ROP treatment
A retrospective cohort review of 48,087 premature infants weighing <1500 gm between 24 to 27 weeks gestation, from 11 high income countries in Australia, New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK . By...
ROP ocular outcomes after Bevacizumab treatment
The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of...
ROP incidence and treatment profile over time
The primary aims of this study were to report the incidence of severe ROP and its treatment in infants <27 and 30 weeks gestational age. Secondary aims were to compare this data with three previously reported cohorts: 2003-2005; 200/2550 with...
Aflibercept, bevacizumab or ranibizumab for DMO
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
